Temsirolimus

FDA Approved: * July 30, 2018
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Temsirolimus Overview

Temsirolimus (codenamed CCI-779) is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the U.S. Food and Drug Administration (FDA) in late May 2007,[2] and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative and prodrug of sirolimus and is sold as Torisel. Contents 1 Mechanism of action 2 Efficacy 3 Adverse reactions 4 Lung toxicity 5 Dosing 6 See also 7 Referenc...

Read more Temsirolimus Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Temsirolimus

Recent Temsirolimus Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

NDC Database Records for Temsirolimus: (1 result)

Sorted by National Drug Code

• 16729-223 Temsirolimus Kit by Accord Healthcare Inc.

Other drugs which contain Temsirolimus or a similar ingredient: (1 result)

• TORISEL Temsirolimus1 discussion

Related Temsirolimus Topics: